Compare Summit Therapeutics Inc (SMMT) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Sprott Uranium Miners ETF — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: Summit Therapeutics Inc is far larger — about 7.3× Sprott Uranium Miners ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Sprott Uranium Miners ETF for 61 Days on average.
| SMMT | URNM | |
|---|---|---|
Market Cap | $13.71B | $1.87B |
Volume | 6,173,057 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $26.38 | $83.99 |
52-Week Low | $12.43 | $46.09 |
Typical Hold Time | 16 Days | 61 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
URNM trades at $46.50, down 2.86% today amid bearish technical signals with 19 sell indicators versus 4 buy. The ETF faces resistance near $47 while finding support at $45-46 levels. Recent news highlights uranium's long-term growth potential driven by AI energy demand and nuclear expansion, though short-term volatility persists.
The uranium mining ETF benefits from structural supply deficits and government nuclear investments, but faces near-term price pressure. Key risks include commodity price volatility and execution challenges among constituent miners. Analyst sentiment remains mixed with bullish long-term themes offset by technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
